HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Related articles in BJP Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Simeon, D. Articles by Knutelska, M. Search for Related Content PubMed PubMed Citation Articles by Simeon, D. Articles by Knutelska, M.

Fluoxetine therapy in depersonalisation disorder: randomised controlled trial

Department of Psychiatry, Mount Sinai School of Medicine, New York, New York, USA

Correspondence: Dr Daphne Simeon, Psychiatry, Box 1230, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA. Tel: +01 (212) 241 7477; fax: +01 (212) 427 6929; e-mail: daphne.simeon{at}mssm.edu

Declaration of interest None.

Background Despite anecdotal reports that serotonin reuptake inhibitors may improve depersonalisation, there is no proven efficacious treatment for depersonalisation disorder.

Aims To investigate the efficacy of fluoxetine in the treatment of depersonalisation disorder.

Method Fifty-four people who met DSM–IV criteria for depersonalisation disorder were recruited through newspaper advertisements, and 50 were randomised to a 10-week, double-blind trial of fluoxetine 10–60 mg/day or placebo. Primary outcome measures were the Dissociative Experiences Scale – Depersonalisation Factor, the Depersonalization Severity Scale and the Clinical Global Impression – Improvement (CGI–I) scale.

Results Intention-to-treat analysis revealed that fluoxetine (mean dosage 48 mg/day) was not superior to placebo except for a clinically minimal but statistically significantly greater improvement in CGI–I score in the fluoxetine group prior to covarying for anxiety and depression (2.9 v. 3.6). Depersonalisation was significantly more likely to improve if comorbid anxiety disorder improved.

Conclusions Fluoxetine was not efficacious in treating depersonalisation disorder, despite the commonly reported clinical use of serotonin reuptake inhibitors for this condition.

Related articles in BJP:

Highlights of this issue

BJP 2004 185: 1-a3. [Full Text]  

Peter Tyrer
BJP 2004 185: 92. [Full Text]  

This article has been cited by other articles:

				E. Lemche, A. Anilkumar, V. P. Giampietro, M. J. Brammer, S. A. Surguladze, N. S. Lawrence, D. Gasston, X. Chitnis, S. C. R. Williams, M. Sierra, et al. Cerebral and autonomic responses to emotional facial expressions in depersonalisation disorder The British Journal of Psychiatry, September 1, 2008; 193(3): 222 - 228. [Abstract] [Full Text] [PDF]

				P. Tyrer, N. Coombs, F. Ibrahimi, A. Mathilakath, P. Bajaj, M. Ranger, B. Rao, and R. Din Critical developments in the assessment of personality disorder The British Journal of Psychiatry, May 1, 2007; 190(49): s51 - s59. [Abstract] [Full Text] [PDF]

				N. Medford, M. Sierra, D. Baker, and A. S. David Understanding and treating depersonalisation disorder Advan. Psychiatr. Treat., March 1, 2005; 11(2): 92 - 100. [Abstract] [Full Text] [PDF]

				SSRI Ineffective for Depersonalization Disorder Journal Watch Psychiatry, August 19, 2004; 2004(819): 5 - 5. [Full Text]